← Leaderboards
Yo-El S Ju
Washington University
$21,872,970
Attributed
$24,925,143
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $12.7M · FY2015–25$20M$15M$10M$5M$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$53,727,956 · 7
By mechanism
U19$45,952,313 · 3
RF1$3,694,308 · 1
R01$2,013,377 · 1
R34$1,178,603 · 1
K23$889,355 · 1
Top collaborators
- Bradley F Boeve7 shared
- Ronald Postuma4 shared
- David M Holtzman1 shared
- Erik Steven Musiek1 shared
Most similar at Washington University
Same institution · by research overlap
- John Morris$91,785,862
- Howard J Edenberg$27,305,449
- Ernesto Bernal-Mizrachi$11,762,416
- James B Skeath$26,614,879
- Christopher F Basler$44,557,002
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposAmericanS DiseaseCohortBiological MarkersClinical TrialsCerebrospinal FluidCollectionProtocols DocumentationCommunitiesPreventBrainParticipantSleep DisordersLinkNeurodegenerative DisordersSenile PlaquesRem Sleep Behavior DisorderMultiple System AtrophyResourcesAffectParkinson DiseaseAmyloid Beta-ProteinPathogenesis
Grant awards (22)
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$6,952,731
U19 · FY2025 · AG · contact PI
NAPS2 Administrative Core$4,185,073
U19 · FY2025 · AG · contact PI
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$7,100,969
U19 · FY2023 · AG · contact PI
NAPS2 Administrative Core$4,251,441
U19 · FY2023 · AG · contact PI
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$7,016,272
U19 · FY2022 · AG · contact PI
NAPS2 Administrative Core$4,174,867
U19 · FY2022 · AG · contact PI
Sleep and Electroencephalography Biomarkers of Alzheimer's Disease$423,167
R01 · FY2022 · AG · contact PI
North American Prodromal Synucleinopathy Consortium for RBD, Stage 2 (NAPS2)$7,732,841
U19 · FY2021 · AG · contact PI
NAPS2 Administrative Core$4,538,119
U19 · FY2021 · AG · contact PI
Sleep and Electroencephalography Biomarkers of Alzheimer's Disease$384,934
R01 · FY2021 · AG · contact PI
Sleep and Electroencephalography Biomarkers of Alzheimer's Disease$418,014
R01 · FY2020 · AG · contact PI
Sleep and Circadian Rhythms in Alzheimer Disease: Potential bi-directional relationship with tau$3,694,308
RF1 · FY2019 · AG
Neuroprotective Treatment Trial Planning in REM Sleep Behavior Disorder$424,342
R34 · FY2019 · AG · contact PI
Sleep and Electroencephalography Biomarkers of Alzheimer's Disease$383,354
R01 · FY2019 · AG · contact PI
Neuroprotective Treatment Trial Planning in REM Sleep Behavior Disorder$342,752
R34 · FY2019 · AG · contact PI
TARGETING SLOW WAVE SLEEP TO CONTROL NEURONAL ACTIVITY AND AMYLOID-BETA DYNAMICS$177,007
K23 · FY2019 · NS · contact PI
Neuroprotective Treatment Trial Planning in REM Sleep Behavior Disorder$411,509
R34 · FY2018 · AG · contact PI
Sleep and Electroencephalography Biomarkers of Alzheimer's Disease$403,908
R01 · FY2018 · AG · contact PI
TARGETING SLOW WAVE SLEEP TO CONTROL NEURONAL ACTIVITY AND AMYLOID-BETA DYNAMICS$178,087
K23 · FY2018 · NS · contact PI
TARGETING SLOW WAVE SLEEP TO CONTROL NEURONAL ACTIVITY AND AMYLOID-BETA DYNAMICS$178,087
K23 · FY2017 · NS · contact PI
TARGETING SLOW WAVE SLEEP TO CONTROL NEURONAL ACTIVITY AND AMYLOID-BETA DYNAMICS$178,087
K23 · FY2016 · NS · contact PI
TARGETING SLOW WAVE SLEEP TO CONTROL NEURONAL ACTIVITY AND AMYLOID-BETA DYNAMICS$178,087
K23 · FY2015 · NS · contact PI